12:30 PM — 1:00 PM

Box Lunch Provided

1:00 PM — 3:30 PM

New Designs for Phase I Trials

• Better Models for Dose Escalation
  Lee Rosen, MD - University of California, Los Angeles
  
  
• Expansion Cohorts as a Means for Activity Signal
  Jeffrey Infante, MD - Sarah Cannon Research Institute
  
  
• Is Oral Administration Really Necessary for Tyrosine Kinase Inhibitors?
  Amita Patnaik, MD - START
  
  
• Pharmacogenomics in Early Drug Development
  Howard McLeod, PharmD - University of North Carolina
  
  
• Circulating Tumor Cells in Phase I Studies: Pros and Cons
          Pro: Timothy Yap, MD - Royal Marsden Hospital
          Con: Jean-Charles Soria, MD, PhD – Gustave Roussy Institute

3:30 PM — 4:00 PM

Break

4:00 PM — 5:00 PM

Reducing the Cost and Time of New Drug Development

• How to Perform Early Clinical Trials Faster and Cheaper
  Anthony Tolcher, MD - START
  
  
• Early Biomarker Development
  Elizabeth Mansfield, MD - U. S. Food and Drug Administration
   

8:00 AM — 8:30 AM

Continental Breakfast Provided

8:30 AM — 8:50 AM

Emerging Concepts of Drug Safety in Oncology

Tatiana Prowell, MD - Sidney Kimmel Comprehensive Cancer Center

8:50 AM — 12:00 PM

Practical Information on Recently Approved Drugs for the Practicing Physician

• Vemurafenib
  Keith Flaherty, MD - Massachusetts General Hospital
   
• Crizotinib
  D. Ross Camidge, MD, PhD - University of Colorado Denver
   
• Brentuximab Vedotin
  Anas Younes, MD - M. D. Anderson Cancer Center
   
• Abiraterone
  Kim Chi, MD - BC Cancer Agency
   
• Ipilimumab
  Jeffrey Weber, MD, PhD - H. Lee Moffitt Cancer Center
   
• Axitinib
  Brian Rini, MD - Cleveland Clinic
   
• Vismodegib
  Ramesh Ramanathan, MD - Virginia G. Piper Cancer Center